Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Combined With SBRT as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
NCT07352007Phase 2Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in hepatocellular carcinoma (HCC). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07352007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07352007.